Efficacy of a Spatial Repellent for Control of *Aedes*-Borne Virus Transmission:

A Cluster Randomized Trial in Iquitos, Peru

Amy C. Morrison, Ph.D.[1,2+], Robert C. Reiner Jr., Ph.D.[3+], William H. Elson,

M.B.B.S.[4], Helvio Astete, M.S.[2], Carolina Guevara, M.S.[2], Clara del Aguila, B.S.[5],

Isabel Bazan, M.D.[2], Crystyan Siles, M.D.[2], Patricia Barrera, M.S.[2], Anna B.

Kawiecki, M.S.[1], Christopher M. Barker, Ph.D.[1], Gissella M. Vasquez, Ph.D.[6], Karin

Escobedo-Vargas, B.S.[6], Carmen Flores-Mendoza, Ph.D.[6], Alfredo A. Huaman,

B.S.[2], Mariana Leguia, Ph.D.[7], Maria E. Silva, Ph.D.,[2] Sarah A. Jenkins, Ph.D.[2],

Wesley R. Campbell, M.D.[2], Eugenio J. Abente, Ph.D.[2], Robert D. Hontz, Ph.D.[2],

Valerie A. Paz-Soldan, Ph.D.[8], John P. Grieco, Ph.D.[9], Neil F. Lobo, Ph.D.[9+], Thomas

W. Scott, Ph.D.[4+], and Nicole L. Achee, Ph.D.[9+*]

[1] Department of Pathology, Microbiology, and Immunology, School of Veterinary
Medicine, University of California, Davis, California, USA

[2] Department of Virology and Emerging Infectious Diseases, U.S. Naval Medical
Research Unit No. 6, Lima, Peru

[3] Department of Health Metrics Sciences, University of Washington, Seattle,
Washington, USA

[4] Department of Entomology and Nematology, University of California, Davis,
California, USA

[5] Dirección General de Saneamiento Ambiental (DIGESA), Calle Alzamora 410,

Iquitos, Peru

[6] Department of Entomology, U.S. Naval Medical Research Unit No. 6, Lima, Peru

[7] Genomics Laboratory, Pontificia Universidad Católica del Perú, Av. Universitaria
1801, San Miguel, Lima, Peru

[8] Department of Global Community Health and Behavioral Sciences, Tulane School
of Public Health and Tropical Medicine, New Orleans, Louisiana, USA

[9] Department of Biological Sciences, Eck Institute for Global Health, University of
Notre Dame, 239 Galvin Life Sciences Center. Notre Dame, Indiana, USA

[+]Indicates equal seniority

*Corresponding author:

Nicole L. Achee, PhD

Research Professor

Eck Institute for Global Health

Department of Biological Sciences

239 Galvin Life Science Center

Notre Dame, Indiana 46556

Ph: 574.631.1561

Email: nachee@nd.edu

ABSTRACT

Background: Over half the world's population is at risk for viruses transmitted by

Aedes mosquitoes, such as, dengue and Zika. The primary vector, *Aedes aegypti*,

thrives in urban environments. Despite decades of effort, cases and the geographic

range of *Aedes*-borne viruses (ABV) continue to expand. Rigorously proven vector

control interventions that measure protective efficacy against ABV diseases is limited

to *Wolbachia* in a single trial in Indonesia, and do not include any chemical

intervention. Spatial repellents, a new option for efficient deployment, are designed to

decrease human exposure to ABV by releasing active ingredients into the air that

disrupt mosquito-human contact.

Methods: A parallel, cluster-randomized controlled trial was conducted in Iquitos,

Peru to quantify the impact of a transfluthrin-based spatial repellent on human ABV

infection. From 2,907 households across 26 clusters (13 per arm), 1,578 participants

were assessed for seroconversion (primary endpoint) by survival analysis. Incidence

of acute disease was calculated among 16,683 participants (secondary endpoint). Bi-

monthly adult mosquito collections were conducted to compare *Ae. aegypti*

abundance, blood-fed capture rate and parity status through mixed effect difference-

in-difference analyses. This trial is registered with ClinicalTrials.gov, number

NCT03553277.

Findings: The spatial repellent significantly reduced ABV infection by 34·1% (95% CI

6·9%, ∞); p = 0·0236, z=1·98). *Aedes aegypti* abundance and blood-fed capture

rates were significantly reduced by 28·6% (95% CI 24·1%, ∞); z=-9·11) and 12·4%

(95% CI 4·2%, ∞); z=-2·43), respectively.

Interpretations: Our trial provides the first conclusive evidence of significant protective

efficacy by any chemical vector control intervention, in this case a spatial repellent, to

reduce the risk of ABV transmission. Results support vector control as a beneficial

component to ABV disease prevention.

Funding: Bill & Melinda Gates Foundation, Military Infectious Disease Program

(MIDRP), Defense Threat Reduction Agency (DTRA), and US National Institutes of

Health.

Introduction

Aedes-borne viral diseases (ABVD) [e.g., dengue (DENV), chikungunya (CHIKV),

Zika (ZIKV), and yellow fever (YF)] are devastating, expanding global public health

threats that disproportionally affect low- and middle-income countries. Currently, the

primary means for ABVD prevention is controlling the primary mosquito vector*, Aedes*

aegypti. Existing vector control interventions, however, have failed to prevent ABV

transmission and epidemics. Dengue alone, one of the most rapidly increasing

vector-borne infectious diseases,[1,2] with four billion people at risk of infection

annually,[3] results in ~400 million infections each year.[2]

There is an urgent need to develop evidence-based guidance for the use of new and

existing ABV vector control tools. The evidence-base for vector control against ABVs

is weak, despite considerable government investments in WHO-recommended

control of larval habitats (larviciding, container removal) and ultra-low volume (ULV)

insecticide spraying.[4–8] These strategies continue to be implemented despite the lack

of rigorously generated data from controlled clinical trials demonstrating they reduce

ABV infection and disease.[9] The only ABV intervention with a proven epidemiological

impact in a cluster randomized control trial (cRCT) assessed community mobilization

to reduce mosquito larval habitats.[10] A recent test-negative trial with *Wolbachia*-

infected mosquitoes reported a significant reduction of dengue illness in Indonesia.[11]

Spatial repellents (SR) are devices that contain volatile active ingredients that

disperse in air. The active ingredients can repel mosquitoes from entering a treated

space, inhibit attraction to human host cues or disrupt mosquito biting and blood

feeding behavior, and, thus, interfere with mosquito-human contact.[12–14] Any of these

outcomes reduce the probability of pathogen transmission. Pyrethroid-based spatial

repellents have shown efficacy in reducing malaria infections in China[15] and

Indonesia.[16] There have, however, been no clinical trials evaluating the protective

efficacy of spatial repellents against ABV infection or disease.

To generate evidence for public health consideration we conducted a parallel, cluster-

randomized controlled trial (cRCT) to quantify the epidemiological impact of a

transfluthrin-based spatial repellent against ABV transmission in Iquitos, Peru.

Methods

The trial is registered at clinicaltrials.gov (NCT03553277).

ETHICAL STATEMENT

Our study protocol (#NAMRU6.2014.0021, Supplementary Information (SI)) was

approved by the U.S. Naval Medical Research Unit No. 6 (NAMRU-6) Institutional

Review Board (IRB), which includes Peruvian representation and complies with US

Federal and Peruvian regulations governing the protections of human subjects, and

the Regional Health Authority (DIRESA), the local branch of the Peruvian Ministry of

Health. IRB authorization agreements were established between the NAMRU-6, the

University of Notre Dame (Sponsor), the University of California at Davis, and the

University of Washington.

TRIAL DESIGN

Detailed study methods are provided in the SI.

Our trial was conducted from June 2015 through March 2019 in the Iquitos and

Punchana Districts of Iquitos, Peru (Figure 1, SI Section 1.1). Clusters were selected

in January 2015. Enrollment began June 2015. Participation included: 1) a house

census, 2) disease surveillance, 3) annual blood draws, 4) bi-monthly entomological

surveys, and 5) intervention application in the house. Epidemiological monitoring and

entomological surveillance lasted from February 2016 through March 2019 (Figure 2).

Our main objective was to demonstrate and quantify the protective efficacy (PE) of a

SR in reducing ABV infection incidence in a human cohort. Qualifying participants

were individuals in a participating house who were seronegative or had a monotypic

DENV antibody response when they entered the trial. Assuming the probability of

seroconversion for seronegative or monotypic individuals was 10% with a coefficient

of variation of 0·25, and an alpha of 5%, we estimated we would need 26 clusters (13

per arm) with approximately 60 qualifying individuals to achieve a power of 80% to

detect a reduction in the odds of 30%.

The primary endpoint was ABV seroconversion, as measured by DENV- or ZIKV-

specific neutralizing antibodies, in blood from children $\geq$ 2 years to $\leq$ 18 years. To

increase the pool of baseline seronegative participants, we expanded screening to

≥18 years. Secondary endpoints were clinically apparent laboratory confirmed ABV

disease and indoor female *Ae.* aegypti: 1) abundance, 2) blood-fed status (proxy for

human-biting rates), and 3) parity status (proxy for age-structure). Participants

followed for seroconversion were the 'longitudinal cohort' and those followed for

disease were the 'febrile surveillance cohort'.

RANDOMIZATION AND INTERVENTION

A total of 26 clusters (13 per arm) each with approximately 140 households (60

qualifying participants) were randomly allocated in August 2016 to receive SR or

placebo intervention by the external statistician serving on the Data Safety Monitoring

Board (DSMB) using a random number generator (https://www.random.org) (SI

Section 1.2.1). Investigators, research staff, and study participants were blinded to

cluster allocation. Our intervention was a transfluthrin passive emanator designed

and produced by SC Johnson (Racine, WI), replaced at 2-week intervals, as

described previously (Figure S1, SI Section 1.3.2).[16] Spatial repellent and placebo

intervention had identical packaging and were deployed in houses by study personnel

using a blinded coding scheme. The placement of the intervention followed

manufacturer specifications for indoor use conditions.

SEROCONVERSION AND DISEASE SURVEILLANCE

Recruitment for the longitudinal cohort focused on children because they were likely

to be antibody test-negative or monotypic at baseline, which would facilitate

interpretation of laboratory assays, and less mobile than adults[17], thus spending more

time in their houses or their assigned cluster. Baseline blood samples were obtained

within 2 weeks before or after initial intervention deployment. As new families moved

into the study area, they were recruited to participate, resulting in longitudinal

participant enrollment throughout the interval between Baseline (B), First (F), and

Second/Final (S) longitudinal blood draws (Figure 3). Samples were tested by

microneutralization enzyme immunoassay (MNT) for seroconversion to each DENV

serotype and ZIKV (SI Sections 1.3.3.1 and 1.3.4.1). Only participants that provided

at least 2 blood samples were included in final analyses.

The febrile surveillance cohort was recruited by nurse technicians during door-to-door

wellness starting with the first week of intervention deployment. Suspected cases

exhibited axillary temperature of ≥ 37·5°C or, for suspected ZIKV infection, absence

of fever but presence of rash, arthralgia, arthritis, or non-purulent conjunctivitis for ≤

five days. Participants meeting these criteria provided acute and convalescent (14–21

days later) serum samples and were monitored clinically daily. Acute serum samples

were tested for viral RNA by PCR (DENV and ZIKV; SI Sections 1.3.3.2-1.3.3.4) and

by ELISA for DENV IgM (SI Sections 1.3.3.5,1.3.4.2).

ENTOMOLOGICAL ENDPOINTS

Indoor Prokopack aspirations[18] were conducted in all consented homes at time of first

intervention deployment and subsequent intervention replacement; i.e., two-week

intervals. Adult mosquitoes were transported to the NAMRU-6 Iquitos laboratory,

sedated at 4°C, identified to species and sex, counted by date and house. Up to 30

female *Ae. aegypti* per household per collection were examined for blood meal status

and scored as unfed, blood-fed (fully engorged, half-engorged, or trace amounts), or

gravid[19]. Standard insecticide resistance assays were used to assess vector

susceptibility to transfluthrin one-year into the trial (SI Section 1.3.5.2).

SAFETY MONITORING

Adverse events (AEs) and serious adverse events (SAEs) were actively collected

throughout the trial during surveillance follow-up and entomological surveys (SI

Section 1.3.6). Reported AEs were investigated by study staff and appropriate care

was recommended by a study physician within 24 hours. Safety reporting to the

NAMRU-6 IRB was managed by UC Davis in accordance with the approved protocol.

Quarterly reports summarizing reported AEs and SAEs were reviewed by the DSMB

for trial safety assessment.

STATISTICAL ANALYSIS

Details of our analytical approach are provided in the statistical analysis plan (SAP)

and SI Section 1.5. All analyses were conducted by RCR using R 3.6.1 (R Core

Team)[20] and the lme4[21] and survival[22] packages. No correction for multiple testing

was performed for secondary endpoint analyses and, as such, in accordance with

CONSORT guidelines, we do not present p-values.

The primary analysis was an intent-to-treat (ITT) assessment of ABV seroconversion

for all qualifying participants per treatment assignment who were >2 years to <18

years of age. Due to the rolling nature of enrollment, we used a survival analysis with

a proportional hazards model and exponential distribution assumption for the

baseline hazard (i.e., constant baseline hazard through time) and a frailty component

to account for correlation within clusters. If $h(t_{ij}|x_{ij})$ is the hazard rate of the jth

individual in the ith cluster with covariate values x_{ij} then this individual's hazard rate

of an arbovirus infection can be written as:

$$h(t_{ij}\,|\,x_{ij}) = h_0\,(t_{ij})\cdot\exp(\beta^T x_{ij} + W_i)$$

where $W_i \sim N(0,\sigma_c^2)$ is the random effect of the ith cluster. Covariates included age,

sex, and treatment status (SR or placebo). PE was estimated as $PE =$

$(1 - \exp(\hat{\beta})) \times 100\%$, where $\hat{\beta}$ is the estimated regression coefficient for the

intervention group and $\exp(\hat{\beta})$ is the estimated hazard ratio (HR) between SR and

placebo. The null hypothesis of PE = 0% is equivalent to $\beta = 0$, which is tested by

Wald's test $z = \beta/s$, where s is the estimated standard error of $\hat{\beta}$, at the 1-sided

significance level of 5%.

A Poisson generalized linear regression was used to assess intervention impact on

clinical disease, with an offset for the number of participant-days each participant

spent in each cluster. No covariates were used and due to the small sample size, no

random effects were incorporated.

Indoor adult female *Ae. aegypti* abundance, blood-fed rates, and parity were tested

through a difference-in-difference Poisson generalized linear mixed models.

Collections conducted in 2016 were defined as 'baseline' and collections conducted

in 2017 and 2018 were estimated as 'post-baseline'. Each analysis accounted for

month of year and year as fixed effects and contained a random effect by cluster.

Model formulation details are in SI Sections 1.5.4-1.5.6.

The primary analysis conducted differs from that in the original SAP (SI SAP).

Procedures called for yearly blood draws from children. To increase the number of

qualifying participants, an expansion of the age range to all ages $\geq$ 2yrs. The rolling

enrollment resulted in substantial variation in time intervals between blood draws.

Simple logistic regression, therefore, was inadequate. The decision to alter the

primary analysis was discussed and agreed upon by the study statistician and the

external DSMB statistician before outputs were unblinded to the DSMB statistician.

Results

STUDY POPULATION

A total of 2,215 persons were enrolled in the longitudinal cohort. Of these, 1,578

qualifying participants were included in the ITT analysis for seroconversion (Figure 3)

representing a total of 196 ABV infections from 754 (1,090 paired samples) qualifying

participants in the SR arm and 294 ABV infections from 824 (1,237 paired samples)

qualifying participants in the placebo arm. Baseline covariates were balanced at both

the cluster and individual level (Table 1).

A total of 16,707 participants were followed for clinical disease, of which 16,683 were

included in the ITT analysis (Figure S2). Baseline covariates for analysis of the

secondary endpoint were balanced at both the cluster and individual level (Table S4).

INTERVENTION COVERAGE

The household participation rate (intervention deployed at some point during the

study period) per cluster (SR and placebo) was of 56·6 % (SD = 10·5%), with slightly

more participation in SR versus placebo clusters (58·8% v 54·5%, p-value = 0·336).

In households consenting to receive intervention (SR or placebo), the mean

percentage of days covered by an intervention at the cluster-level was 81·6% (SD =

3·9), with slightly higher coverage in households assigned to SR intervention (82·9%)

compared to households in the placebo arm (80·3%), albeit insignificant (p-value =

0·153, Table S2, Figure S3). For all enrolled households, the mean percentage of

days with an adequate intervention application rate (1 product per 9 m^2) was 73·6%

(SD = 9·1), with similar rates between SR and placebo clusters (72·7% versus

74·5%, p-value > 0·999, Table S2).

SPATIAL REPELLENT EFFICACY

The estimated PE of SR intervention was 34·1% (1-sided 95% CI lower limit, 6·9%;

(Table 2). Reduction in the arbovirus infection hazard rate was significant at the 5%

significance level (Test statistic: z=1·98, 1-sided p-value = 0·02). Baseline covariates

included in the statistical model on the hazard of arbovirus infection in qualifying

participants were age, which had statistically significant effects on the hazard of

arbovirus infection in qualifying participants, and sex, which did not. Hazard rate

increases by 4·6% for every one-year increase in age. Hazard rate decreases by

4·4% in males relative to females (Table 2). The originally proposed ITT mixed

effects logistic regression analysis, which ignores differential participation duration

across qualifying participants, produced a result consistent with those presented

here; i.e., PE > 30% and statistical significance at the 5% level (Table 2).

The Kaplan-Meier curves of arbovirus infection for qualifying participants by cluster

show considerable between-cluster variation (SR and placebo clusters) as evidenced

by the wide spread of survival curves (Figure 4). For example, there were no

arbovirus infections in qualifying participants in one placebo cluster; Cluster 7.2 had

only 18 qualifying participants. Conversely, in Cluster 8.2 almost half of the qualifying

participants with duration between serologic tests exceeded 15 months became

infected (5/11). The duration between tests varied by participant and across clusters

(Figure S4), resulting in some Kaplan-Meier curves being estimated beyond two

years. In many of those clusters, the only participants that went over two years

between blood sampling were universally found to have had an arboviral infection.

There were 96 disease cases detected, 51 in the SR arm and 45 in the placebo arm,

from 10,793,792 participant days that appeared balanced between SR and placebo

clusters (Table S4).

The estimated reduction adult female *Ae. aegypti* abundance in clusters receiving SR

intervention was 28·6% (1-sided 95% CI lower limit: 24·1%, test statistic: z= -9·11)

(Table 3). Baseline mosquito abundance was balanced between treatment arms

(Table S5) with post-baseline quantities estimated based on 47,518 and 43,417

household collections in SR and placebo arms, respectively. Baseline abundance

averaged 0·277 (standard deviation [SD] 0·153) and 0·279 (SD 0·122) per house

survey in SR and placebo arms, respectively, whereas post-baseline abundance

averaged 0·276 (SD 0·091) and 0·391 (SD 0·142) in the SR and placebo arms,

respectively (Table 3). There was a strong indication of seasonality, with z-scores

comparing each month to the reference month of January being at least 6 away from

0 (Table S7). Overall, abundance trended lower in the SR clusters compared to the

placebo clusters after intervention deployment from 2017-2019, the duration of the

trial (Figure 5).

The estimated reduction in the rate of blood-fed *Ae. aegypti* collected inside houses

was 12·4% (1-sided 95% CI lower limit: 4·2%, test statistic: z= -2·430) (Table 3).

Baseline abundance of engorged *Ae. aegypti* was balanced treatment arms (Table

S5) with post-baseline quantities estimated based on 9,257 and 11,496 mosquitoes

assessed for blood-fed status in SR and placebo arms, respectively. Baseline

abundance of blood-fed mosquitoes averaged 0·593 (standard deviation 0·440) and

0·536 (standard deviation 0·451) per collection in SR and placebo arms, respectively,

and post-baseline rates averaged 0·606 (SD 0·460) and 0·634 (SD 0·447) in SR and

placebo arms, respectively. There was no strong indication of seasonality (Table S8).

There was no observed intervention effect (Table 3) or indication of seasonality

(Table S9) based on the parity rate of *Ae. aegypti* females.

ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE).

There were 29 AEs reported during the trial (SI Section 2.8). Of these, three were

associated with blood draw (vasovagal response, two from SR and one from placebo

clusters) and 26 were consistent with transfluthrin (pyrethroid) exposure (22 from SR

and 4 from placebo clusters). Of the latter, the 26 affected individuals came from 18

households, often reporting different combinations of the following symptoms: allergic

response with itching and skin irritations (n=19; 15 from SR, four from placebo

clusters), dry mouth/bad taste (n=5, from SR clusters only), breathing issues (n=7,

from SR clusters only) including exacerbation of chronic bronchitis or asthma (n=2),

and headaches (n=4, from SR clusters only). No reported SAEs (deaths) were

deemed associated with the spatial repellent intervention.

Discussion

Aedes-borne viruses threats come from multiple viruses, which have expanding

regions of transmission and increasingly frequent epidemics. There is, therefore, a

growing unmet need for effective ABV disease prevention.[9] Our cRCT provides the

first conclusive evidence of significant PE against human ABV infection by any

chemical-based vector control intervention, in this case a spatial repellent.

PE was detected despite assumed dilution and contamination effects due to

participant movement in and out of study clusters. Unlike a vaccine, this intervention

protects the study participant in their own home or another protected home within

their neighborhood (i.e. Study Cluster), but does not provide continuous protection

once they leave treated houses. Our cohort, tested for ABV seroconversion, was

comprised principally of children $\leq$ 17 years of age, most who attended schools which

have been shown to be of lower risk of *Ae. aegypti* infestation than residential sites in

Iquitos.[23] Our outcome was demonstrated in an operational context, reflecting

complex interactions among ongoing Ministry of Health interventions across the study

area, imperfect coverage at the household-level (rooms closed to intervention,

homeowner removal and/or loss of intervention), <100% household participation

within clusters, and suggestion of pyrethroid resistance in the local *Ae. aegypti*

population.[24(SI section 2.7)] Reduced risk of ABV infection was associated with a

significant reduction in indoor female *Ae. aegypti* abundance and blood feeding.

Although entomological outcomes were modest, these effects are consistent with the

expected mode of action of SRs; i.e., deterrence from house entry and/or interfering

with human-biting.[12,25] Our entomological data will help guide indicators for next-

generation product development.

Our results support SRs as a flexible class of vector control products with positive

public health impact not limited to ABV diseases. Transfluthrin-[15] and metofluthrin-

based[16,26] mosquito coils have been shown to reduce malaria and the same spatial

repellent device used in our Iquitos trial reduced malaria infections in an Indonesia

cRCT.[15] Together, these results highlight the potential for SRs to reduce a variety of

vector-borne diseases, augment existing public health efforts and be an effective

component of vector control intervention strategies. To help guide implementation

and programmatic scale-up, additional assessments, which have already begun, [27–30]

are needed.

Our Peru cRCT is one of two trials recommended by the WHO for assessing public

health value and developing global health policy for the SR intervention class.[31] Our

study was powered to detect a 30% reduction in ABV infection risk. During the trial

period, dengue prevalence was lower than previous years and a Zika epidemic

occurred in 2016.[32] This uncertainty is typical of ABV transmission, making powering

of cRCTs challenging and helps explain why, until now, ABV cRCTs with

epidemiological outcomes have been rare.[33] We used seroconversion as our primary

endpoint of PE to address this challenge. In our setting, powering a trial based on

clinically apparent ABV disease would not be logistically feasible.

Fully integrating vector control into ABV disease prevention programs will require

quantitative guidance based on quantitative measures of the impact from each

intervention component. Ministries of Health, local to national governments and non-

governmental organizations can use our trial results as an evidence-base for

informed application of SRs. Considering the growing ABV public health threat,

difficulties of developing vaccines against multiple viruses and past, poorly informed

vector control failures,[9] enhanced ABV disease prevention will benefit greatly from

interventions with proven public health value.

Data sharing

De-identified analytical datasets, including deidentified participant data, data

dictionaries and analytical codes, will be made available with publication upon

request to RCR at bcreiner@uw.edu. Open-access distribution of the data will fall

under the terms of the Creative Commons Attribution (CC-BY) License, which permits

unrestricted use, distribution, and reproduction in any medium, provided the original

author and source are credited.

Acknowledgements

We extend sincere appreciation to DSMB members: Dennis Shanks, Chris Drakeley,

and Neal Alexander for assurances on data integrity and safety assessments. We

thank the WHO Vector Control Advisory Group (VCAG) for their comments during

project assessments. We are grateful for the efforts of Marianne Kent, Program

Coordinator at the University of Notre Dame, for her administrative, and logistical

support of the program, as well as, Brett Fox of the University of Notre Dame Center

for Research Computing for assisting with central database development for data

verification. We thank Kristina Davis and Matthew Sisk of the University of Notre

Dame Center for Research Computing and Hesburgh Libraries, respectively, for their

assistance in graphic development. We acknowledge Audrey Lenhart of the Centers

for Disease Control and Prevention (CDC) in Atlanta, GA USA and J. Kevin Baird of

the Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia and Nuffield

Department of Medicine, Centre for Tropical Medicine, University of Oxford, Oxford,

United Kingdom for their role on the Scientific Advisory Committee.

We express our gratitude to the Bill and Melinda Gates Foundation for their long-term

generosity and support of spatial repellent product evaluation and development,

especially Kate Aultman, Dan Strickman, and Alan Magill. We are deeply grateful to

SC Johnson for providing integral industry and product expertise including the

independent funding of the development, manufacturing, delivery, and shipment of

the intervention (SR and placebo) used in the study. SC Johnson provided expertise

in ensuring intervention quality, storage, application and disposal assurances

throughout the trial.

We thank the residents of Iquitos for their support and participation in this study and

willingness to allow this study to be conducted in their community. We greatly

appreciate support of the Loreto Regional Health Department including Drs. Hugo

Rodriguez-Ferruci, Christian Carey, Carlos Alvarez, and Lic. Wilma Casanova Rojas,

who facilitated our work in Iquitos. We thank the NAMRU-6 Virology and Emerging

Infections Department (VEID) leadership who provided institutional support, IRB

guidance, and support supervising field staff. We appreciate the careful commentary

and advice provided by the NAMRU-6 IRB and Research Administration Program for

the duration of this study. We thank the NAMRU-6 VEID field who provided daily

support through the duration of the project and without whom the recruitment of acute

dengue cases would not have been possible. In particular, we thank Cecilia

Gonzales, Gloria Talledo, and Gabriela Vasquez de la Torre for their administrative

support of the project.

Author contributions

Data were gathered by the field team in Iquitos (ACM, WHE, HA, IB, CS, and ABK);

laboratory testing by CG, PB, and AH; insecticide resistance testing by GMV, KEV,

and CFM; and human use issues were managed by ACM, SAJ, and WRC. ML

developed a Zika virus PCR assay used in the study. CDA provided Ministry of

Health entomological information and coordinated activities with Iquitos field teams.

The NAMRU-6 supervisory team in Lima included MS, SAJ, WRC, EJA, and RHD.

CM provided data management and ZIKV MNT laboratory testing. Statistical analysis

was conducted by RCR. The first draft of the manuscript was written by ACM, RCR,

TWS, and NLA, with revision following comments from all the authors.

Copyright statement

Disclaimer

469 The views expressed in this article are those of the author and do not necessarily

470 reflect the official policy or position of the Department of the Navy, Department of

471 Defense, nor the U.S. Government.

Financial disclosure statement

This study was funded by the Bill and Melinda Gates Foundation (BMGF) to the

University of Notre Dame (Grant# OPP1081737). Further support was provided by

the Defense Threat Reduction Agency (DTRA), Military Infectious Disease Research

Program (MIDRP, S0520_15_LI and S0572_17_LI), and the U.S. National Institute of

Allergy and Infectious Diseases (NIH/NIAID) award number P01 AI098670. SC

Johnson used internal company financial resources for the development,

manufacturing, delivery, and shipment of the intervention (SR and placebo) used in

the study.

Competing interests

484 The authors have declared that no competing interests exist.

References

1   Murray CJL, Barber RM, Foreman KJ, *et al.* Global, regional, and national
disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life
expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological
transition. *Lancet* 2015; **386**: 2145–91.

2   Stanaway JD, Shepard DS, Undurraga EA, *et al.* The global burden of dengue: an
analysis from the Global Burden of Disease Study 2013. *Lancet Infect Dis* 2016; **16**:
712–23.

3   Bhatt S, Gething PW, Brady OJ, *et al.* The global distribution and burden of
dengue. *Nature* 2013; **496**: 504–7.

4   Parks W, Lloyd L. Planning social mobilizaiton and communication for dengue
fever prevention and control. Geneva: WHO, 2004.

5   Esu E, Lenhart A, Smith L, Horstick O. Effectiveness of peridomestic space
spraying with insecticide on dengue transmission; systematic review. *Trop Med Int*
Health 2010; **15**: 619–31.

6   Horstick O, Runge-Ranzinger S, Nathan MB, Kroeger A. Dengue vector-control
services: how do they work? A systematic literature review and country case studies.
Trans R Soc Trop Med Hyg 2010; **104**: 379–86.

7   Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in
Effectiveness or Evidence?: Systematic Review and Meta-analysis. *PLoS Negl Trop*
Dis 2016; **10**: e0004551.

8   Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges
and proposing solutions for control of the virus vector Aedes aegypti. *PLoS Med*
2008; **5**: e68.

9   Achee NL, Gould F, Perkins TA, *et al.* A critical assessment of vector control for
dengue prevention. *PLoS Negl Trop Dis* 2015; **9**: e0003655.

10 Andersson N, Nava-Aguilera E, Arostegui J, *et al.* Evidence based community
mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the
Green Way): cluster randomized controlled trial. *BMJ* 2015; **351**: h3267.

11 Utarini A, Indriani C, Ahmad RA, *et al.* Efficacy of Wolbachia-infected mosquito
deployments for the control of dengue. *N Engl J Med* 2021; **384**: 2177–86.

12 Achee NL, Bangs MJ, Farlow R, *et al.* Spatial repellents: from discovery and
development to evidence-based validation. *Malar J* 2012; **11**: 164.

13 World Health Organization. WHO pesticide evaluation scheme. World Health
Organization, 2013 http://www.who.int/iris/handle/10665/78142.

14 WHO | Vector Control Advisory Group. 2020; published online Oct 6.
https://www.who.int/vector-control/vcag/en (accessed Nov 26, 2020).

15 Hill N, Zhou H, Wang P, Guo X, Carneiro I, Moore SJ. A household randomized,
controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination
with long-lasting insecticidal nets on the incidence of Plasmodium falciparum and
Plasmodium vivax malaria in Western Yunnan Province, China. Malaria Journal.
2014; **13**: 208.

16 Syafruddin D, Asih PBS, Rozi IE, *et al.* Efficacy of a Spatial Repellent for Control
of Malaria in Indonesia: A Cluster-Randomized Controlled Trial. *Am J Trop Med Hyg*
2020; published online May 18. DOI:10.4269/ajtmh.19-0554.

17 Vazquez-Prokopec GM, Bisanzio D, Stoddard ST, *et al.* Using GPS technology to
quantify human mobility, dynamic contacts and infectious disease dynamics in a
resource-poor urban environment. *PLoS One* 2013; **8**: e58802.

18 Vazquez-Prokopec GM, Stoddard ST, Paz-Soldan V, *et al.* Usefulness of
commercially available GPS data-loggers for tracking human movement and
exposure to dengue virus. *Int J Health Geogr* 2009; **8**: 68.

19 Gunning CE, Okamoto K, Astete H, *et al.* Efficacy of Aedes aegypti control by
indoor Ultra Low Volume (ULV) insecticide spraying in Iquitos, Peru. *PLoS Negl Trop*
Dis 2018; **12**: e0006378.

20 R Core Team. R: A language and environment for statistical computing. R
Foundation for Statistical Computing. Vienna, Austria, 2019 http://www.R-project.org/.

21 Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models
using lme4. arXiv [stat.CO]. 2014; published online June 23.
http://arxiv.org/abs/1406.5823.

22 Therneau TM. A Package for Survival Analysis in S. version 2.38. 2015; published
online Sept 28. http://cran.r-project.org/package=survival (accessed Jan 19, 2021).

23 Morrison AC, Sihuincha M, Stancil JD, *et al.* Aedes aegypti (Diptera: Culicidae)
production from non-residential sites in the Amazonian city of Iquitos, Peru. *Ann Trop*
Med Parasitol 2006; **100 Suppl 1**: S73–86.

24 Palomino-Salcedo M. [Estado de susceptibilidad de la población natural de Aedes
aegypti a los insecticidas en Punchana-Iquitos, Región Loreto (Novimbre 2014).
Instituto Nacional de Salud, Peru, 2014.

25 Norris E, Coats J. Current and future repellent technologies: The potential of
spatial repellents and their place in mosquito-borne disease control. *Int J Environ Res*
Public Health 2017; **14**: 124.

26 Syafruddin D, Bangs MJ, Sidik D, *et al.* Impact of a spatial repellent on malaria
incidence in two villages in Sumba, Indonesia. *Am J Trop Med Hyg* 2014; **91**: 1079–
87.

27 Liverani M, Charlwood JD, Lawford H, Yeung S. Field assessment of a novel
spatial repellent for malaria control: a feasibility and acceptability study in Mondulkiri,
Cambodia. *Malar J* 2017; **16**: 412.

28 Masalu JP, Finda M, Okumu FO, *et al.* Efficacy and user acceptability of
transfluthrin-treated sisal and hessian decorations for protecting against mosquito
bites in outdoor bars. *Parasit Vectors* 2017; **10**: 197.

29 Paz-Soldan VA, Plasai V, Morrison AC, *et al.* Initial assessment of the
acceptability of a Push-Pull Aedes aegypti control strategy in Iquitos, Peru and
Kanchanaburi, Thailand. *Am J Trop Med Hyg* 2011; **84**: 208–17.

30 Jumbam DT, Stevenson JC, Matoba J, *et al.* Knowledge, attitudes and practices
assessment of malaria interventions in rural Zambia. *BMC Public Health* 2020; **20**:
216.

31 World Health Organization. The evaluation process for vector control products.
World Health Organization, 2017 https://apps.who.int/iris/handle/10665/255644
(accessed Dec 2, 2020).

32 https://www.paho.org/hq/dmdocuments/2017/2017-phe-zika-situation-report-
per.pdf (Accessed Dec 2, 2020).

33 Anders KL, Cutcher Z, Kleinschmidt I, *et al.* Cluster-Randomized Test-Negative
Design Trials: A Novel and Efficient Method to Assess the Efficacy of Community-
Level Dengue Interventions. *Am J Epidemiol* 2018; **187**: 2021–8.

Figure 1. Location of 26 study clusters in Iquitos and Punchana Districts, Loreto
Department, Iquitos, Peru. Each cluster consisted of ca. 140 households with an
average distance of 300m between clusters.

Figure 2. Study timeline. Top panel: Human blood-sampling, disease surveillance,
and entomological monitoring in relation to deployment of the spatial repellent
intervention. Bottom panel: Intervention roll-out between August-December 2016 by
cluster. Horizontal numbers correspond to cluster numbers shown in Figure 1.

Figure 3. Allocation and follow-up of the longitudinal cohort population during three blood collection periods (Baseline [B], First [F] and Second/Final [S]). The majority (62%) of participants provided samples at each collection period, whereas some only participated during year 1 (B-F) or year 2 (F-S). Participants with a single sample were lost to follow-up and four individuals moved or had two houses located in the spatial repellent and placebo clusters are shown as removed at the baseline period for clarity.

Figure 4. Kaplan-Meier curves of arbovirus infection for 13 spatial repellent (SR) and
13 placebo clusters in qualifying participants measured by seroconversion (primary
endpoint) by cluster.

Figure 5. Mean densities of adult female *Aedes aegypti* collected per household survey in 13 spatial repellent (SR) and
13 placebo clusters by study month. Shaded areas represent the 95% Confidence Interval around the mean.

Table 1. Summary of baseline characteristics, for qualifying participants of the intent-to-treat (ITT) longitudinal cohort
population in spatial repellent (SR) and placebo arms. Qualifying participants were defined as individuals in a participating
house who were seronegative or had a monotypic DENV antibody response when they entered the trial.

Individual-Level		
Variable	SR (n=898)	Placebo (n=952)
Age in years (mean±sd) (min, max)	10·88±4·62 (2, 47)	10·19±4·39 (2, 22)
Sex (% male)	51·6%	55·0%
Duration in years between samples (mean±sd) (min, max)	1·15±0·42 (0·02 ,2·29)	1·16±0·43 (0·01, 2·35)
No. qualifying participant observations	1,090	1,237
No. of arbovirus seroconversions	196	294
Cluster-Level		
Variable	SR (n=13)	Placebo (n=13)
Cluster population (mean±sd) (min, max)	58·2±30·4 (21,124)	73·5±35·3 (12,132)
Baseline susceptibility (mean±sd) (min, max)	81·0%±12·8% (54·7%,98·1%)	84·9%±6·3% (73·3%,92·5%)

612 **Table 2.** Protective efficacy (PE) estimates from intent to treat (ITT) analyses for the spatial repellent intervention against
613 *Aedes*-borne virus infection in qualifying participants measured by seroconversion (primary endpoint), including covariate
614 effects.

ITT analysis	Hazard rate ratio (95% CI)	PE (%) (95% CI)	One-sided p-value	Covariate	Odds ratio (95% CI)	Two-sided p-value
Survival analysis	0·659 (−∞,0·931)	34·1 (6·9,∞)	0·024			
				Age	1·046 (1·029-1·063)	$6·8 \times 10^{-6}$
				Male	0·956 (0·821-1·112)	0·62
ITT analysis	**Odds ratio (95% CI)**	**PE (%) (95% CI)**	**One-sided p-value**	**Covariate**	**Odds ratio (95% CI)**	**Two-sided p-value**
Odds reduction	0·547 (−∞,0·883)	45·3 (11·7,∞)	0·019			
				Age	1·071 (1·042-1·100)	$6·9 \times 10^{-7}$
				Male	0·950 (0·767-1·177)	0·64
Odds reduction on including 9–15-month sampling intervals	0·577 (−∞,0·879)	42·3 (12·1,∞)	0·016			
				Age	1·065 (1·028-1·103)	0·0005
				Male	0·970 (0·767-1·299)	0·779

616 **Table 3.** Rate reduction summary of indoor adult female *Aedes aegypti* abundance, blood-fed female abundance, and
617 parity rates (secondary endpoints) for primary (ITT) and secondary analyses (PP). No correction for multiple testing was
618 performed for secondary endpoint analyses and, as such, in accordance with CONSORT guidelines p-values are not
619 presented.

Indicator	Statistics	2016 Baseline[1]		Cluster-specific Baseline[2]	
		ITT	PP	ITT	PP
Indoor adult female *Aedes aegypti* abundance	Rate ratio (95% one-sided CI)	0·714 (−∞,0·759)	0·737 (−∞,0·784)	0·599 (−∞,0·633)	0·607 (−∞,0·641)
	Rate reduction (%) (95% one-sided CI)	28·6 (24·1,∞)	26·3 (16·2,∞)	40·1 (36·7,∞)	39·3 (35·9,∞)
Blood-fed female *Aedes aegypti* abundance	Rate ratio (95% one-sided CI)	0·876 (−∞,0·958)	0·876 (−∞,0·958)	0·908 (−∞,0·985)	0·929 (−∞,1·06)
	Rate reduction (%) (95% one-sided CI)	12·4 (4·2,∞)	12·4 (4·2,∞)	9·20 (1·49,∞)	7·10 (-6,∞)
Aedes aegypti parity rate	Rate ratio (95% one-sided CI)	0·922 (−∞,1·057)	0·921 (−∞,1·056)	0·928 (−∞,1·058)	0·909 (−∞,0·986)
	Rate reduction (%) (95% one-sided CI)	7·75 (-5·70,∞)	7·87 (-5·60,∞)	7·24 (-5·80,∞)	9·10 (-1·2,∞)

[1] Intent to treat (ITT, primary analysis) and per protocol (PP, secondary analysis) mixed effects difference-in-difference
(DID) Poisson regression specifying measurements made throughout 2016 as 'baseline', with post-2016 measurements
as 'post-baseline.' PP analysis only considering houses with SR application rates meeting manufactures specifications
≥75% of the days between sequential blood sampling (designated PP-1).

[2] ITT and PP mixed effects DID Poisson regression specifying measurements made in 2016 up to the first date of
intervention deployed in each cluster as 'baseline' with all measurements following that date as 'post-baseline' for that
cluster, even for houses that did not enroll until 2017 or later. PP analysis only considering houses with SR application
rates meeting manufactures specifications ≥75% of the days between sequential blood sampling (designated PP-1).